Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

80.18
+1.251.58%
Pre-market: 80.440.2600+0.32%06:40 EDT
Volume:774.06K
Turnover:62.18M
Market Cap:6.55B
PE:-21.73
High:82.03
Open:77.51
Low:77.24
Close:78.93
52wk High:103.00
52wk Low:19.45
Shares:81.64M
Float Shares:54.63M
Volume Ratio:0.99
T/O Rate:1.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6900
EPS(LYR):-3.6900
ROE:-25.78%
ROA:-15.87%
PB:4.14
PE(LYR):-21.73

Loading ...

Kymera Therapeutics to Participate in Upcoming February Investor Conferences

GlobeNewswire
·
Feb 04

Kymera Therapeutics: KT-621’s Differentiated Efficacy and Safety Profile Underpins Attractive Risk-Reward in Emerging Oral Atopic Dermatitis Market

TIPRANKS
·
Feb 03

Kymera Therapeutics Price Target Maintained With a $138.00/Share by BTIG

Dow Jones
·
Feb 03

Kymera Therapeutics initiates dosing in BREADTH Phase 2b trial of KT-621

TIPRANKS
·
Jan 29

Kymera Therapeutics Doses First Patient in Phase 2b Asthma Trial of KT-621

Reuters
·
Jan 29

Kymera Therapeutics Inc - Expects Breadth Trial Data in Late-2027

THOMSON REUTERS
·
Jan 29

Kymera Therapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
Jan 28

Kymera Therapeutics assumed with an Overweight at Barclays

TIPRANKS
·
Jan 28

TD Cowen Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

TIPRANKS
·
Jan 16

Kymera Therapeutics Price Target Maintained With a $138.00/Share by BTIG

Dow Jones
·
Jan 15

Kymera Therapeutics Announces 2026 Strategy to Advance Oral Immunology Pipeline, Launch New Development Candidate, and Initiate Key Clinical Trials

Reuters
·
Jan 13

Kymera Therapeutics Inc: Intends to Advance at Least One New Development Candidate Towards Ind for a First-in-Class, Oral Immunology Program in 2026

THOMSON REUTERS
·
Jan 13

Kymera Therapeutics Inc: Well-Capitalized With $1.6 Billion1in Cash and Runway Into 2029

THOMSON REUTERS
·
Jan 13

Kymera Therapeutics Presents 2026 Objectives at J.P. Morgan Healthcare Conference

Reuters
·
Jan 13

Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

GlobeNewswire
·
Jan 13

A Look At Kymera Therapeutics (KYMR) Valuation After KT-621 Trial Update And J.P. Morgan Conference Focus

Simply Wall St.
·
Jan 12

Kymera Therapeutics Cut to Peer Perform From Outperform by Wolfe Research

Dow Jones
·
Jan 06

Kymera Therapeutics CEO Nello Mainolfi Reports Sale of Common Shares

Reuters
·
Jan 01

Did KT-621 Fast Track Status Just Shift Kymera Therapeutics' (KYMR) Investment Narrative?

Simply Wall St.
·
Dec 22, 2025

Kymera Therapeutics Inc : B. Riley Raises Target Price to $117 From $80

THOMSON REUTERS
·
Dec 22, 2025